Caribou Biosciences Stock Cash Per Share
| CRBU Stock | USD 0.95 0.07 6.86% |
Caribou Biosciences fundamentals help investors to digest information that contributes to Caribou Biosciences' financial success or failures. It also enables traders to predict the movement of Caribou Stock. The fundamental analysis module provides a way to measure Caribou Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Caribou Biosciences stock.
Caribou |
Caribou Biosciences Company Cash Per Share Analysis
Caribou Biosciences' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Caribou Biosciences Cash Per Share | 5.59 X |
Most of Caribou Biosciences' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Caribou Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Caribou Biosciences has a Cash Per Share of 5.59 times. This is 28.51% higher than that of the Biotechnology sector and 29.1% higher than that of the Health Care industry. The cash per share for all United States stocks is 11.58% lower than that of the firm.
Caribou Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Caribou Biosciences' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Caribou Biosciences could also be used in its relative valuation, which is a method of valuing Caribou Biosciences by comparing valuation metrics of similar companies.Caribou Biosciences is currently under evaluation in cash per share category among its peers.
Caribou Fundamentals
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (18.43) % | ||||
| Current Valuation | (94.61 M) | ||||
| Shares Outstanding | 93 M | ||||
| Shares Owned By Insiders | 10.08 % | ||||
| Shares Owned By Institutions | 61.64 % | ||||
| Number Of Shares Shorted | 8.91 M | ||||
| Price To Book | 0.35 X | ||||
| Price To Sales | 8.85 X | ||||
| Revenue | 9.99 M | ||||
| Gross Profit | (119.56 M) | ||||
| EBITDA | (166.62 M) | ||||
| Net Income | (149.1 M) | ||||
| Cash And Equivalents | 339.92 M | ||||
| Cash Per Share | 5.59 X | ||||
| Total Debt | 26.49 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 12.23 X | ||||
| Book Value Per Share | 2.74 X | ||||
| Cash Flow From Operations | (138.2 M) | ||||
| Short Ratio | 7.92 X | ||||
| Earnings Per Share | (1.65) X | ||||
| Price To Earnings To Growth | 0.50 X | ||||
| Target Price | 12.88 | ||||
| Number Of Employees | 147 | ||||
| Beta | 2.34 | ||||
| Market Capitalization | 88.44 M | ||||
| Total Asset | 313.31 M | ||||
| Retained Earnings | (448.39 M) | ||||
| Working Capital | 188.73 M | ||||
| Net Asset | 313.31 M |
About Caribou Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Caribou Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Caribou Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Caribou Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Caribou Stock Analysis
When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.